The diagnostic imaging of hepatocellular carcinoma (HCC) has recently undergone marked progress. The advent of the ultrasound (US) contrast agent Sonazoid, approved in January 2007, and magnetic resonance imaging (MRI) with the liver-specific MRI contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA-MRI), approved in January 2008, are of particular significance. Sonazoid contrast-enhanced US (Sonazoid-CEUS) is useful not only for the diagnosis of HCC, but also for guiding treatment and assessing treatment response. Sonazoid-CEUS has proven to be particularly effective for screening and staging, which used to be considered impossible with CEUS, through the introduction of the newly developed diagnostic technique of defect reperfusion imaging. It is still not possible if other vascular agents such as SonoVue and Definity are used. In particular, Gd–EOB-DTPA-MRI has been suggested to be much more reliable in the differentiation of early HCC from precancerous dysplastic nodules than any other modalities such as multidetector raw computed tomography, dynamic MRI, and superparamagnetic iron oxide-MRI. A decrease in contrast uptake in the hepatocyte phase observed on EOB-MRI is strongly suggestive of cancer, and the absence of early staining in the arterial phase suggests early HCC. The differential diagnostic capacity of Gd-EOB-DTPA-MRI is considered to far exceed that of what were previously the most useful imaging techniques, computed tomography (CT) during hepatic arteriography or CT during arterial portography, and to be comparable to that of the pathological diagnosis by pathologists specialized in liver.

1.
Kudo M: Contrast Harmonic Imaging in the Diagnosis and Treatment of Hepatic Tumors. Tokyo, Springer, 2003, pp 1–253.
2.
Kudo M, Hatanaka K, Maekawa K: Defect reperfusion imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J Med Ultrasound 2008;16:169–175.
3.
Kudo M, Hatanaka K, Maekawa K: Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78(suppl 1):40–45.
4.
Makuuchi M, Kokudo N, Arii S, Igaki H, Ikai I, Kaneko S, et al: Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma. Hepatol Res 2010;40(suppl 1):1–144.
5.
Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guideline Proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339–364.
6.
Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
7.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.
8.
Hatanaka K, Chung H, Kudo M, Haji S, Minami Y, Maekawa K, et al: Usefulness of the post-vascular phase of contrast-enhanced ultrasonography with sonazoid in the evaluation of gross types of hepatocellular carcinoma. Oncology 2010;78(suppl 1):53–59.
9.
Hatanaka K, Kudo M, Minami Y, Maekawa K: Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008;75(suppl 1):42–47.
10.
Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T: Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011;106:368–370.
11.
Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, et al: Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51:S61–69.
12.
Wen YL, Kudo M, Zheng RQ, Ding H, Zhou P, Minami Y, et al: Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am J Roentgenol 2004;182:1019–1026.
13.
Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K: Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode. Radiology 2001;220:349–356.
14.
Inoue T, Kudo M, Watai R, Pei Z, Kawasaki T, Minami Y, et al: Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2005;40:1139–1147.
15.
Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K: Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2001;176:661–666.
16.
Minami Y, Kudo M, Kawasaki T, Kitano M, Chung H, Maekawa K, et al: Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003;180:703–708.
17.
Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Chung H, et al: Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 2001;221:721–730.
18.
Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H: Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol 2004;183:153–156.
19.
Minami Y, Kudo M, Chung H, Kawasaki T, Yagyu Y, Shimono T, et al: Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am J Roentgenol 2007;188:489–494.
20.
Wen YL, Kudo M, Zheng RQ, Minami Y, Chung H, Suetomi Y, et al: Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003;181:57–63.
21.
Minami Y, Kudo M, Hatanaka K, Kitai S, Inoue T, Hagiwara S, et al: Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience. Liver Int 2010;30:759–764.
22.
Minami Y, Kudo M: Hepatic malignancies: correlation between sonographic findings and pathological features. World J Radiol 2010;2:249–256.
23.
Kudo M: Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010;78(suppl 1):113–124.
24.
Inoue T, Minami Y, Chung H, Hayaishi S, Ueda T, Tatsumi C, et al: Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases. Oncology 2010;78(suppl 1):94–101.
25.
Minami Y, Kudo M: Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocelular carcinomaprimary hepatocelular carcinoma. World J Radiol 2009;31:86–91.
26.
Kudo M: Local ablation therapy for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2004;39:205–214.
27.
Zhou P, Kudo M, Minami Y, Chung H, Inoue T, Fukunaga T, et al: What is the best time to evaluate treatment response after radiofrequency ablation of hepatocellular carcinoma using contrast-enhanced sonography? Oncology 2007;72(suppl 1):92–97.
28.
Minami Y, Chung H, Kudo M, Kitai S, Takahashi S, Inoue T, et al: Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. AJR Am J Roentgenol 2008;190:W335–341.
29.
Minami Y, Kudo M, Chung H, Inoue T, Takahashi S, Hatanaka K, et al: Percutaneous radiofrequency ablation of sonographically unidentifiable liver tumors. Feasibility and usefulness of a novel guiding technique with an integrated system of computed tomography and sonographic images. Oncology 2007;72(suppl 1):111–116.
30.
Minami Y, Kudo M: Radiofrequency ablation of hepatocellular carcinoma: current status. World J Radiol 2010;2:417–424.
31.
Kawata S, Murakami T, Kim T, Hori M, Federle MP, Kumano S, et al: Multidetector CT: diagnostic impact of slice thickness on detection of hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 2002;179:61–66.
32.
Haider MA, Amitai MM, Rappaport DC, O’Malley ME, Hanbidge AE, Redston M, et al: Multi-detector row helical CT in preoperative assessment of small (< or =1.5 cm) liver metastases: is thinner collimation better? Radiology 2002;225:137–142.
33.
Kim T, Murakami T, Hori M, Takamura M, Takahashi S, Okada A, et al: Small hypervascular hepatocellular carcinoma revealed by double arterial phase CT performed with single breath-hold scanning and automatic bolus tracking. AJR Am J Roentgenol 2002;178:899–904.
34.
Murakami T, Kim T, Takamura M, Hori M, Takahashi S, Federle MP, et al: Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology 2001;218:763–767.
35.
Ichikawa T, Kitamura T, Nakajima H, Sou H, Tsukamoto T, Ikenaga S, et al: Hypervascular hepatocellular carcinoma: can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver? AJR Am J Roentgenol 2002;179:751–758.
36.
Laghi A, Iannaccone R, Rossi P, Carbone I, Ferrari R, Mangiapane F, et al: Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003;226:543–549.
37.
Francis IR, Cohan RH, McNulty NJ, Platt JF, Korobkin M, Gebremariam A, et al: Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR Am J Roentgenol 2003;180:1217–1224.
38.
Lee KH, O’Malley ME, Haider MA, Hanbidge A: Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol 2004;182:643–649.
39.
Tanikake M, Shimizu T, Narabayashi I, Matsuki M, Masuda K, Yamamoto K, et al: Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent. Radiology 2003;227:883–889.
40.
Lee SS, Kim TK, Byun JH, Ha HK, Kim PN, Kim AY, et al: Hepatic arteries in potential donors for living related liver transplantation: evaluation with multi-detector row CT angiography. Radiology 2003;227:391–399.
41.
Kalra MK, Maher MM, Blake MA, Lucey BC, Karau K, Toth TL, et al: Detection and characterization of lesions on low-radiation-dose abdominal CT images postprocessed with noise reduction filters. Radiology 2004;232:791–797.
42.
Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsunaga N: Cirrhosis or chronic hepatitis: evaluation of small (< or =2 cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003;226:550–555.
43.
Ito K, Fujita T, Shimizu A, Koike S, Sasaki K, Matsunaga N, et al: Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am J Roentgenol 2004;183:699–705.
44.
Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, et al: Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res 2003;27:196–204.
45.
Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al: Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205–212.
46.
Ba-Ssalamah A, Schima W, Schmook MT, Linnau KF, Schibany N, Helbich T, et al: Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am J Roentgenol 2002;179:1447–1456.
47.
Mori K, Scheidler J, Helmberger T, Holzknecht N, Schauer R, Schirren CA, et al: Detection of malignant hepatic lesions before orthotopic liver transplantation: accuracy of ferumoxides-enhanced MR imaging. AJR Am J Roentgenol 2002;179:1045–1051.
48.
Arbab AS, Ichikawa T, Sou H, Araki T, Nakajima H, Ishigame K, et al: Ferumoxides-enhanced double-echo T2-weighted MR imaging in differentiating metastases from nonsolid benign lesions of the liver. Radiology 2002;225:151–158.
49.
Bluemke DA, Weber TM, Rubin D, de Lange EE, Semelka R, Redvanly RD, et al: Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 2003;228:457–464.
50.
Bhartia B, Ward J, Guthrie JA, Robinson PJ: Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 2003;180:577–584.
51.
Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT: Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 2003;228:719–726.
52.
Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al: Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230:266–275.
53.
Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al: Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59–67.
54.
Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S, et al: Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006;47:15–23.
55.
Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al: Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44:793–798.
56.
Tsuda N, Matsui O: Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi – gadoxetic acid-enhanced MR imaging. Radiology 2010;256:767–773.
57.
Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, et al: Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005;4:1–9.
58.
Okada M, Imai Y, Kim T, Kogita S, Takamura M, Kumano S, et al: Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2010;32:903–913.
59.
Kudo M: The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010;439–452.
60.
Kudo M: Will Gd-EOB MRI change the diagnostic algorithm for hepatocellular carcinoma? Oncology 2010;S87–93.
61.
Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al: Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405–2413.
62.
Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y, et al: Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010;45:133–141.
63.
Kojiro M, Wanless I, Alves V, et al: Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658–664.
64.
Imai Y, Murakami T, Hori M, Fukuda K, Kim T, Marukawa T, et al: Hypervascular hepatocellular carcinoma: combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 2008;38:147–158.
65.
Kudo M: Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009;44(suppl 19):112–118.
66.
Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M: Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143–149.
67.
Kudo M, Okanoue T, Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(suppl 1):2–15.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.